Skip to content

Study · Measured the body's own peptide · 1991

2 results

Patients with lower motor spinal cord lesion: a decrease of vasoactive intestinal polypeptide, calcitonin gene-related peptide and substance P, but not neuropeptide Y and somatostatin-immunoreactive nerves in the detrusor muscle of the bladder.

Crowe R, Moss HE, Chapple CR, Light JK, Burnstock G

The Journal of urology1 Mar 1991Cited by 15 (Europe PMC)

PMID1705295 (opens in a new tab)DOI10.1016/s0022-5347(17)38403-3 (opens in a new tab)PepBankPUB-01705295
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Natural levels measured2

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelObservational studyOther

    In patients with lower motor neurone lesion, the density of VIP-immunoreactive nerves in the bladder detrusor muscle was lower than in controls.

    In plain wordsIn patients with a spinal cord lesion, the body's own VIP nerves in the bladder muscle were fewer than in controls.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseDensity of VIP-immunoreactive nerves in detrusor muscle
    Study

    n = 7

    Comparator
    Patients with bladder carcinoma (controls)
    Outcome group
    Receptor activity and mechanism · Kidney and urinary

    Source sentences

    Summary
    In patients with lower motor neurone lesion, there was a decrease in the density of vasoactive intestinal polypeptide-, calcitonin gene-related peptide- and substance P-immunoreactive nerves, but there was little change in neuropeptide Y- or somatostatin-immunoreactive nerves.
    1 context sentence
    Summary · context
    Specimens of the detrusor muscle of the bladder from four patients with lower motor neurone lesion and three patients with carcinoma of the bladder used as "controls", were studied immunohistochemically for vasoactive intestinal polypeptide, neuropeptide Y, calcitonin-gene related peptide, substance P and somatostatin.

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

  2. 02HumanEndogenous levelObservational studyOther

    In control bladder detrusor, VIP-immunoreactive nerves were found throughout the smooth muscle and the base of the mucosa, and around blood vessels.

    In plain wordsIn control patients, the body's own VIP nerves were found through the bladder muscle and around blood vessels.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableDistribution of VIP-immunoreactive nerves in control detrusor
    Study

    n = 7

    Outcome group
    Receptor activity and mechanism · Kidney and urinary

    Source sentences

    Summary
    Neuropeptide Y- and vasoactive intestinal polypeptide-immunoreactive nerves were found throughout the smooth muscle and the base of the mucosa
    2 context sentences
    Summary · context
    Vasoactive intestinal polypeptide-, neuropeptide Y- and calcitonin gene-related peptide-immunoreactive nerves were also located around blood vessels.
    Summary · context
    Specimens of the detrusor muscle of the bladder from four patients with lower motor neurone lesion and three patients with carcinoma of the bladder used as "controls", were studied immunohistochemically for vasoactive intestinal polypeptide, neuropeptide Y, calcitonin-gene related peptide, substance P and somatostatin.

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.